JAPAN TOBACCO INC. (2914) Stock Price

Japan Tobacco Inc. (JT) is a global company with three major business segments: tobacco, pharmaceuticals, and processed foods. These operations are supported by 268 consolidated subsidiaries and 53 equity-method affiliates.

In the tobacco business, JT International S.A. leads the manufacturing and sales of tobacco products across the world. Key subsidiaries include LLC JTI Russia and Gallaher Ltd. JT sells products in over 130 countries and regions and ranks third globally in sales volume.

The pharmaceutical business focuses on research, development, manufacturing, and sales of prescription medicines. Torii Pharmaceutical handles manufacturing and sales, while Akros Pharma Inc. conducts clinical development overseas. Key products include Colechtim Ointment, a treatment for atopic dermatitis.

In the processed foods business, Table Mark manufactures and sells frozen foods and seasonings. Major products include Katokichi Sanuki Udon frozen noodles and Kokusan Koshihikari packaged rice. Fuji Food Industries operates the seasonings business.

Beyond these core operations, Japan Tobacco Inc. also engages in real estate leasing. Each business segment pursues independent strategies in research and development, procurement, manufacturing, and sales to strengthen its competitive position in global markets.

Japan Tobacco Inc. (JT) pursues sustainable profit growth under its management philosophy of the "4S Model," which emphasizes balanced responsibility toward four stakeholders: customers, shareholders, employees, and society. Through this approach, JT aims to enhance corporate value over the medium to long term and actively invests in business operations to support future profit growth.

JT has established "Enriching Life" as its Group Purpose, seeking to remain a company valued by society. Across its tobacco, pharmaceutical, and processed food businesses, JT sets specific business objectives and creates value through the execution of business strategies. This commitment positions JT as a company that continues to contribute to society.

In allocating management resources, JT positions its tobacco business as the core driver of profit growth and prioritizes investment to support sustainable expansion. The pharmaceutical and processed food businesses play complementary roles in overall profit growth, receiving necessary investment. This approach emphasizes balanced management between business investment and shareholder returns.

Under its medium-term management plan "Management Plan 2025," JT expects operating profit growth on a constant currency basis through sustained price increases in the tobacco business and improved profitability of Reduced-Risk Products (RRP). Regarding shareholder returns, JT targets a dividend payout ratio of approximately 75% while maintaining a strong financial foundation and realizing profit growth.

To respond to changing business environments, JT pursues three core strategies: "high-quality top-line growth," "enhanced cost competitiveness," and "foundation strengthening." In the tobacco business particularly, JT concentrates management resources in Combustibles and RRP, expanding market share through brand equity enhancement. This approach supports sustainable growth.

In the pharmaceutical business, JT aims to contribute profits through research and development of next-generation strategic products and value maximization of existing products. In the processed food business, JT pursues profit growth through high-quality top-line expansion. Through these strategies, JT targets sustainable profit growth and enhanced corporate value.